The Kirby-Bauer Disk Diffusion Test: Complete Guide to Method, Interpretation, and Applications

Antimicrobial resistance (AMR) kills an estimated 1.27 million people annually and is projected by the WHO to become the world’s leading cause of death by 2050. At the center of the clinical and public health response to this crisis is antimicrobial susceptibility testing (AST) — and the disk diffusion method developed by Kirby, Bauer, Sherris, and Turck in 1966, universally known as the Kirby-Bauer test, remains the most widely used AST method in the world.

Its enduring dominance across six decades rests on a combination of simplicity, low cost, flexibility, and robustness: it requires no specialized automated equipment, can test multiple antibiotics against a pathogen in a single overnight run, and produces clinically actionable results that directly guide treatment decisions. At the same time, the Kirby-Bauer test is not a static legacy method — its standardizing bodies, CLSI and EUCAST, continuously update breakpoints and interpretation guidelines, most notably EUCAST’s 2019 redefinition of the susceptibility categories.

This comprehensive guide covers everything laboratory professionals, clinicians, quality assurance teams, and researchers need to know about the Kirby-Bauer test — from its scientific foundation and step-by-step methodology to its limitations, comparisons with alternative AST methods, and how ContractLaboratory.com can connect your organization with accredited microbiology contract testing laboratories.

History and Development of the Kirby-Bauer Test

The clinical need for standardized antimicrobial susceptibility testing emerged in the 1940s and early 1950s, as the discovery of penicillin and subsequent antibiotics created an urgent demand for reliable methods to match drugs to pathogens. Early disk diffusion methods existed in various laboratories, but without standardization — different labs used different media, inoculum concentrations, incubation conditions, and disk potencies, generating results that could not be compared or reliably interpreted.

In 1956, W.M.M. Kirby and colleagues at the University of Washington School of Medicine and King County Hospital proposed a single-disk method as a step toward standardization. This work, refined over the following decade, culminated in the landmark 1966 publication: Bauer AW, Kirby WMM, Sherris JC, and Turck M. “Antibiotic susceptibility testing by a standardized single disk method.” American Journal of Clinical Pathology, 45:493–496. This paper established the protocol that the World Health Organization and later national standards bodies codified into the universally adopted test we use today.

The Clinical and Laboratory Standards Institute (CLSI — formerly the National Committee for Clinical Laboratory Standards, or NCCLS) became the primary steward of the test in the United States, publishing and regularly updating its M02 document (“Performance Standards for Antimicrobial Disk Susceptibility Tests”). In Europe, EUCAST was established in 1997 and has since developed its own calibrated disk diffusion methodology, aligned with MIC-based clinical breakpoints and progressively updated, including the Disk Diffusion Manual v12.0 (2024) and Reading Guide v11.0 (2025).

Scientific Principle: How the Kirby-Bauer Test Works

The Kirby-Bauer test operates on the principle of agar diffusion. A filter paper disk impregnated with a defined concentration of an antimicrobial agent is placed on the surface of an agar plate that has been uniformly inoculated with the microorganism under test. The antimicrobial agent diffuses radially outward through the agar, creating a concentration gradient: highest nearest the disk, decreasing logarithmically with distance.

Where the local concentration of the antimicrobial agent exceeds the minimum inhibitory concentration (MIC) of the organism, bacterial growth is inhibited. This creates a clear, circular zone around the disk — the zone of inhibition (ZoI). The diameter of this zone is inversely related to the MIC: lower MIC organisms are more susceptible and produce larger zones; higher MIC organisms produce smaller zones or none at all.

The zone diameter is measured in millimeters and compared against published interpretive breakpoints specific to the drug-organism combination. This comparison categorizes the organism as Susceptible (S), Susceptible at Increased Exposure (I) (EUCAST) / Intermediate (I) (CLSI), or Resistant (R).

One important nuance: zone size is influenced not only by MIC but also by the molecular weight and diffusion properties of the antimicrobial. Smaller, lighter molecules diffuse further through agar, producing larger zones. This is why zone diameter breakpoints are drug-specific — a larger zone for Drug A does not automatically mean greater susceptibility than a smaller zone for Drug B.

Mueller-Hinton Agar: The Standardized Medium

Mueller-Hinton agar (MHA) is the required medium for standard Kirby-Bauer testing, selected for properties that minimize interference with antimicrobial activity and support reproducible results. Its composition — beef heart infusion, casein hydrolysate, and starch — provides nutrients that support broad bacterial growth while containing relatively low levels of thymidine and thymine (which interfere with sulfonamide and trimethoprim testing) and low levels of divalent cations (which affect aminoglycoside and tetracycline results).

Critical technical specifications that must be met for valid results:

• pH: 7.2–7.4 at room temperature. Deviations affect drug activity — low pH reduces aminoglycoside activity and increases tetracycline activity, while high pH has the opposite effect.
• Agar depth: 4 mm. Standardized to a depth of approximately 4 mm per plate (roughly 25 mL per 100 mm plate). Thick agar slows lateral diffusion, producing artificially small zones; thin agar produces artificially large zones.
• Divalent cation content. Calcium and magnesium levels must be within defined ranges (50–100 mg/L for calcium; 20–35 mg/L for magnesium). Excess divalent cations reduce aminoglycoside zones.
• Freshness. Plates should ideally be used within seven days of preparation and stored refrigerated, protected from light.

For fastidious organisms such as Haemophilus influenzae and Neisseria gonorrhoeae, supplemented media are required. Haemophilus Test Medium (HTM) is used for H. influenzae, while GC agar base with defined supplements and CO₂ incubation is used for N. gonorrhoeae. CLSI and EUCAST both publish organism-specific method modifications.

Step-by-Step Procedure

Interpreting Results: Breakpoints, S/I/R Categories, and the EUCAST 2019 Update

What Breakpoints Are

A breakpoint is the zone diameter threshold that separates susceptibility categories. Breakpoints are not arbitrary — they are derived from pharmacokinetic/pharmacodynamic (PK/PD) modeling of drug exposure in vivo, epidemiological cutoff values (ECOFFs) that characterize wild-type susceptibility distributions, and clinical outcome data. Different drugs have different breakpoints for the same organism, and the same drug may have different breakpoints for different organisms. Always use the current version of the CLSI M02 or EUCAST breakpoint table — breakpoints are updated annually.

The EUCAST 2019 Redefinition of Susceptibility Categories

This is the most clinically significant methodological update to AST interpretation in recent years, and the article’s use of EUCAST as an endorsing body makes it essential to address. Since January 2019, EUCAST has formally changed the definition of the “I” category:

• Previous definition (2002–2018): Intermediate. Implied uncertain or borderline efficacy. In practice, many clinicians treated “I” results similarly to “R” and selected an alternative drug — even when higher-dose therapy with the “I” drug might have been appropriate.
• Current EUCAST definition (2019–present): Susceptible, Increased Exposure (I). Means there is a high likelihood of therapeutic success if drug exposure at the infection site is increased — either by optimizing the dosing regimen (e.g., higher dose, extended infusion) or by the drug’s natural pharmacokinetic concentration at the site. Crucially, “I” is now a susceptible category, not a borderline resistant one.

The CLSI continues to use “Intermediate” with its original definition and has not adopted the EUCAST redefinition. Laboratories and clinicians must be aware of which standard they are following when interpreting “I” results, as the clinical implications differ substantially.

Quality Control

Every batch of testing must include quality control (QC) organisms — ATCC reference strains with well-characterized, published zone diameter ranges. Standard QC strains include Staphylococcus aureus ATCC 25923, Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 27853, and Enterococcus faecalis ATCC 29212. If QC zones fall outside the published acceptable ranges, the test run is invalid and must be investigated before reporting patient results. Disk potency, agar quality, incubation conditions, and inoculum preparation are common sources of QC failure.

Kirby-Bauer vs. Other Antimicrobial Susceptibility Testing Methods

The Kirby-Bauer test is one of several established AST methods. Choosing the right method depends on the clinical question, organism type, available resources, and required turnaround time.

Feature	Kirby-Bauer (disk diffusion)	Broth microdilution	E-test (Epsilometer)	Automated AST (VITEK, Phoenix)
Result type	Qualitative (S/I/R)	Quantitative (MIC in mg/L)	Quantitative (MIC) + category	Quantitative MIC + category
Cost	Low	Moderate	Moderate–high	High (capital + reagents)
Equipment needed	Minimal (incubator, calipers)	Microdilution equipment	Incubator only	Automated instrument
Turnaround	16–18 hours	16–20 hours	16–20 hours	4–8 hours (rapid)
Drug flexibility	High — any disk available	High — any dilution panel	High — any E-test strip	Limited to instrument card
MIC value provided	No	Yes (reference standard)	Yes (gradient estimate)	Yes
Standardizing bodies	CLSI M02, EUCAST	CLSI M07, EUCAST	CLSI / EUCAST guidelines	Manufacturer + CLSI/EUCAST
Best use case	Routine clinical, resource-limited settings, research	Gold standard for MIC; reference testing	MIC needed; limited automation	High-volume clinical labs with rapid result needs

An important note on the E-test: The Epsilometer test uses a plastic strip with a predefined antibiotic gradient. It combines the simplicity of disk diffusion with the ability to read an approximate MIC from the point where the elliptical zone of inhibition intersects the strip’s numeric scale. It is particularly useful when a specific MIC is needed for dosing decisions but full broth microdilution is not available. The E-test is not the same as the Kirby-Bauer disk diffusion test and produces different result formats.

Applications of the Kirby-Bauer Test

Clinical Diagnostics

In hospital and reference microbiology laboratories, the Kirby-Bauer test is the primary tool for guiding antibiotic selection in individual patient care. After a pathogen is isolated and identified from a clinical specimen (blood, urine, wound, CSF, sputum), AST results guide the transition from empiric to targeted therapy. This is particularly critical for infections caused by organisms with emerging resistance — such as Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa — where first-line treatment options may be ineffective.

Antimicrobial Stewardship Programs

Antimicrobial stewardship programs (ASPs) in healthcare facilities use aggregate Kirby-Bauer and other AST data to generate antibiograms — annual summaries of local resistance patterns for the most commonly encountered pathogens. Antibiograms guide empirical antibiotic prescribing protocols, inform formulary decisions, and allow facilities to benchmark their resistance rates against regional and national data published by surveillance programs such as the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS). Contract microbiology testing laboratories can provide aggregate AST data to support antibiogram development.

Pharmaceutical Research and Drug Development

In early-stage antibiotic drug development, the Kirby-Bauer test provides a rapid, inexpensive screen for antimicrobial activity of novel compounds. While broth microdilution is preferred for quantitative MIC determination in lead compound selection, disk diffusion is widely used for initial activity screening and for comparative testing of compound libraries. Contract research and pharmaceutical testing laboratories routinely offer Kirby-Bauer screening as part of antimicrobial activity testing packages.

Veterinary and Agricultural Applications

Antimicrobial susceptibility testing of animal pathogens is governed by veterinary-specific CLSI standards (e.g., VET08 for broth microdilution and VET09 for disk diffusion). The Kirby-Bauer method is used in veterinary diagnostic laboratories to guide treatment of companion animal and livestock infections and is an important tool in monitoring zoonotic AMR transmission pathways.

Food Safety and Environmental Surveillance

The Kirby-Bauer test is used in food safety testing to characterize the susceptibility profiles of bacterial isolates recovered from food products, food production environments, and water sources. This is particularly important for tracking AMR in foodborne pathogens such as Salmonella, Campylobacter, and E. coli O157:H7 through the food chain.

Advantages and Limitations

Advantages

• Cost-effectiveness and accessibility. The test requires minimal specialized equipment — an incubator, calipers, and commercially prepared media and disks — making it viable in resource-limited settings where automated AST systems are not available.
• Flexibility in drug selection. Any commercially available antibiotic disk can be tested, giving laboratories control over their drug panels without being constrained by the fixed reagent cards of automated systems.
• Universal standardization. CLSI and EUCAST provide rigorously maintained, annually updated interpretive criteria for hundreds of drug-organism combinations.
• Compatibility with fastidious organisms (supplemented). With appropriate media modifications (HTM, GC agar, supplemented chocolate agar), the test can be extended to challenging clinical pathogens not amenable to automated methods.
• Overnight results. The 16–18 hour turnaround, while not rapid by modern standards, remains clinically acceptable for most routine AST scenarios and is faster than some broth-based MIC methods.

Limitations

• Qualitative results only. The Kirby-Bauer test does not generate a MIC value. For situations where a specific MIC is needed — such as dosing optimization for serious infections, monitoring for emerging resistance, or regulatory submissions — broth microdilution or E-test is required.
• Not suitable for all organisms. Slow-growing organisms, strict anaerobes, and certain fastidious bacteria require modified protocols or alternative methods. Mycobacteria, for example, require specialized AST systems.
• Operator- and environment-dependent variability. Deviations in inoculum density, agar depth, disk placement, incubation temperature, or zone measurement technique can all affect results. Strict adherence to standardized protocols and robust QC programs are essential.
• Cannot determine bactericidal vs. bacteriostatic activity. The zone of inhibition indicates growth inhibition but cannot differentiate between drugs that kill bacteria (bactericidal) and those that merely suppress growth (bacteriostatic). Determining bactericidal activity requires minimum bactericidal concentration (MBC) testing.
• Breakpoints require regular updates. As resistance patterns evolve, CLSI and EUCAST update breakpoints — sometimes reclassifying organisms from susceptible to resistant using updated criteria applied to historical data. Laboratories must use current breakpoint tables and understand that a result valid under last year’s breakpoints may be classified differently under this year’s.

The Kirby-Bauer Test in the Context of Global Antimicrobial Resistance

The WHO’s 2022 Global Antimicrobial Resistance and Use Surveillance System report found that AMR directly caused 1.27 million deaths globally in 2019, with Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa responsible for the majority of AMR-attributable deaths. These six pathogens — all routinely tested by Kirby-Bauer — illustrate the direct public health importance of accurate susceptibility testing.

The WHO’s ESKAPE pathogens — Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species — represent organisms that effectively “escape” current antimicrobial therapies and are priority targets for AST surveillance. The Kirby-Bauer test, interpreted alongside molecular resistance detection (PCR for mecA, ESBL genes, carbapenemase genes), forms the phenotypic backbone of ESKAPE pathogen monitoring in clinical and public health laboratories.

Finding a Contract Laboratory for Kirby-Bauer and Antimicrobial Susceptibility Testing

For healthcare systems, pharmaceutical companies, food producers, agricultural operations, and research institutions requiring Kirby-Bauer testing or broader antimicrobial susceptibility testing services, ContractLaboratory.com connects organizations with accredited contract microbiology laboratories worldwide.

When evaluating a contract laboratory for AST services, key criteria include: CLIA certification or equivalent national accreditation for clinical testing; ISO/IEC 17025 accreditation for testing and calibration if results will support regulatory submissions; documented use of current CLSI M02 or EUCAST disk diffusion methodology; established QC programs with ATCC reference strains; and experience with the specific organism classes and drug panels relevant to your application.

You can submit a laboratory testing request describing your testing requirements and receive proposals from qualified laboratories. Browse our directory by testing type or product category, or contact our team for expert guidance.

Frequently Asked Questions About the Kirby-Bauer Test

Conclusion

The Kirby-Bauer disk diffusion test has remained at the center of clinical microbiology practice for six decades because it strikes an optimal balance between scientific rigor and practical accessibility. It is simple enough to run in a resource-limited laboratory and robust enough to generate results that guide treatment decisions in the world’s leading academic medical centers — provided it is performed in strict accordance with CLSI or EUCAST standardized protocols.

As antimicrobial resistance continues to escalate globally, the importance of accurate, standardized susceptibility testing only grows. Staying current with breakpoint updates — particularly EUCAST’s 2019 redefinition of the susceptibility categories — and maintaining rigorous QC programs are essential professional responsibilities for every laboratory performing Kirby-Bauer testing. For organizations seeking accredited contract microbiology laboratories for Kirby-Bauer testing, antimicrobial susceptibility panels, or broader antimicrobial resistance testing services, ContractLaboratory.com can connect you with the right laboratory partner. Submit a testing request or contact our team to get started.